Case Report

Detection of *Mycoplasma columbinasale* in Cases of Respiratory Disease in Domestic Pigeons (*Columba livia* var. *domestica*)

Giuseppe Giglia,1,2 Ilaria Porcellato,1 Maria Luisa Marenzoni,1 Elisa Rampacci,1 Marco Bottinelli,3 Andrea Matucci,3 Fabrizio Passamonti,1 and Elvio Lepri1

1Department of Veterinary Medicine, University of Perugia, Via San Costanzo 4, 06126 Perugia, Italy
2Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL, Utrecht, Netherlands
3Mycoplasma Unit-SCTI-Verona, WOAHI, Reference Laboratory for Avian mycoplasmosis, Istituto Zooprofilattico Sperimentale delle Venezie, Via Bovolino 1c, 37060 Buttapietra, Italy

Correspondence should be addressed to Giuseppe Giglia; g.giglia@uu.nl

Received 17 February 2022; Revised 25 May 2022; Accepted 27 October 2022; Published 19 November 2022

Academic Editor: Giuseppe Mazzullo

Copyright © 2022 Giuseppe Giglia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In 2017, respiratory disease and low mortality were reported in domestic flying pigeons (*Columba livia* var. *domestica*) trained as hunting live bait in a breeding farm in Umbria, Italy. Clinically, open beak breathing, dropped wings, and pharyngeal and laryngeal hyperaemia were observed. Three birds were submitted for necropsy. Gross pathological evaluation revealed in all cases diffuse hyperaemia of the tracheal mucosa in association with mild emaciation and multiorgan congestion. Microscopically, diffuse epithelial hyperplasia of the trachea (n = 3) and diffuse lymphocytic infiltration of the lamina propria (n = 3) were observed. No lesions were reported in other organs. Based on reported clinical signs and lesions, *Mycoplasma* spp. were suspected, and molecular detection was performed on tracheal specimens leading to the identification of *M. columbinasale*. Immunohistochemistry was subsequently performed to localize the microorganism within tissue lesions. Immunohistochemistry confirmed the presence of *Mycoplasma* species on the tracheal epithelial cells of all birds. Following tylosin administration, complete resolution of the clinical condition and lack of recurrence of clinical signs were reported in the breeding farm. These findings suggest that *M. columbinasale* could potentially have a role in the respiratory disease and low mortality in domestic pigeons.

1. Introduction

*Mycoplasma* organisms are small bacteria lacking a cell wall. *Mycoplasma* species have been incriminated as cause of diseases in numerous animal species and can cause significant economic losses in livestock [1]. Transmission can be vertical or horizontal, the latter through airborne dust and secreted droplets [2]. In avian species, numerous *Mycoplasma* spp. (e.g., *Mycoplasma gallisepticum*, *M. synoviae*, *M. meleagridis*, and *M. iowae*) are reported as cause of diseases, especially in chickens and turkeys. In pigeons, the role of *Mycoplasma* spp. is still unclear, with described isolation of *M. columbinum*, *M. columborale*, and *M. columbinasale* in both clinically healthy birds and birds showing respiratory clinical signs [3–7]. Furthermore, reports of mycoplasma-associated disease in pigeons are few and often lack a clear association between agent and lesion. Here, we describe the detection of *Mycoplasma columbinasale* in an outbreak of respiratory disease and mortality in domestic pigeons (*Columba livia* var. *domestica*) in central Italy in 2017, describing postmortem, gross pathological, and microscopic evaluation, in association with molecular and immunohistochemical identification of the microorganism.

2. Case Presentation

2.1. Case History and Gross Post-Mortem Examination. In 2017, a breeding farm of flying pigeons (*Columba livia* var. *domestica*), trained as hunting live bait, reported signs of respiratory disease in 10% of birds, in association with low
mortality (3%) and overall poor performance, in Umbria (Italy). Animals were vaccinated against *Avian Paramyxovirus* type 1 (APMV-1). Clinically, birds were showing open beak breathing, increased respiratory effort, wheezing, and dropped wings. Signs were waxing and waning following long-term unsuccessful treatment cycles with sulphonamides, nitroimidazoles (Sulfamethoxazole Trimethoprim and dimetridazole), and quinolones (Enrofloxacine 10%). During clinical examination, the clinician reported diffuse and moderate pharyngeal and laryngeal hyperaemia in association with the previously mentioned signs. Nestlings were not affected, while first signs of disease were developed after weaning, concurrently with the initial phase of training. Three spontaneously dead birds with respiratory signs were submitted to the Veterinary Pathology Diagnostic Service of the Department of Veterinary Medicine in Perugia (Italy) for postmortem investigation. Complete necropsies were performed with concurrent gross examination. In all three examined animals, subtle gross changes were observed. Mild emaciation with reduced fat deposits and mild bilateral pectoral muscle atrophy were identified. A mild and diffuse dark-red discoloration and organomegaly were seen in liver and spleen (congestion). A diffuse light-red discoloration was noticed in the lung and tracheal mucosa, the latter also showing a diffuse, mild to moderate, increased thickness. No other lesions or changes were observed in other organs.

2.2. Histology and Immunohistochemistry. Tissues from all organs were sampled for pathology and immersion-fixed in 10% neutral-buffered formalin during necropsy, or stored at -20°C, for subsequent molecular testing. For histology, formalin-fixed tissues were embedded in paraffin and, subsequently, 5 μm sections were cut and stained with routine Haematoxylin and Eosin stain. For the immunohistochemistry, briefly, 5 μm sections were cut from the three cases and mounted on poly-L-lysine-coated slides. After dewaxing and rehydration, slides were pretreated in a microwave with Tris-EDTA buffer (pH 9.0) for 20 minutes and, after cooling, washed with phosphate-buffered saline (PBS) and incubated with a mouse monoclonal antibody pan-avian *Mycoplasma* MAB-IZSVE-PANMYC-137 (cross-reactive with different avian *mycoplasma* species) diluted 1 : 500 for 2 hours at room temperature. After Tris-buffered saline (TBS) washing, slides were treated with a diluted biotinylated secondary antibody for 30′; subsequently, ABC ready-to-use kit (Abcam, Cambridge, UK) was used according to the manufacturer’s instructions. Positive reaction was revealed with 3-amino-9-ethylcarbazole (Abcam). Mayer’s haematoxylin was applied as a counterstain. Negative controls were incubated with TBS, omitting the primary antibody. Ovine *Mycoplasma* sp. PCR-positive lungs with lesions compatible with mycoplasma-associated disease were used as positive control. On histology, in all birds, the most striking lesion was identified in the trachea, which showed a diffuse and marked epithelial hyperplasia, in association with loss of cilia and multifocal areas of erosion (Figure 1(a)). A moderate and diffuse inflammatory infiltrate was expanding an oedematous lamina propria. The inflammatory infiltrate was characterized by a high number of small mature lymphocytes, with occasional histiocytes and rare plasma cells.

**Figure 1:** Histology and immunohistochemical detection of *Mycoplasma* spp. in domestic pigeons. (a) Trachea (H&E); marked epithelial hyperplasia and increased cellularity of the lamina propria and multifocal areas of erosion and ulceration. (b) Trachea (H&E); submucosal lymphoid aggregates. (c) Lung (H&E); mononuclear aggregates are characterized by small lymphocytes (short blue arrowhead), plasma cells (long black arrowhead), macrophages (long orange arrowhead), and occasional heterophils (short green arrowhead). (d) Trachea (IHC); *Mycoplasma* spp. seen as finely granular intracytoplasmic reaction on the respiratory epithelium.
Multifocally, submucosal lymphoid aggregates were prominent (Figure 1(b)). Moderate changes were also noticed on the vessels of the lamina propria, showing moderate ectasia with a high number of circulating erythrocytes (hyperaemia). The bronchial lamina propria of the lungs showed diffuse and marked accumulation of amorphous weakly eosinophilic to basophilic material (oedema). Multifocal lymphoid aggregates of varying size as well as the infiltration of a moderate number of small lymphocytes, occasional mature heterophils, and rare histiocytes were also present in one case (Figure 1(c)). The surrounding pulmonary parenchyma showed diffuse and moderate hyperaemia and aerial capillaries with the occasional presence of oedema. Only in one case was noticed a focal area characterized by loss of the tissue architecture and replacement with eosinophilic amorphous material mixed with pyknotic nuclei and cellular debris (colliquiative necrosis), surrounded by numerous macrophages, epithelioid cells and in smaller numbers, multinucleated giant cells of the “foreign body” type (granuloma). In the air sacs of all cases, occasional small mature lymphocytes and histiocytes infiltrating the stroma were observed, while the lining epithelium appeared multifocally, mildly hyperplastic. Of the other organs, only the liver showed a diffuse and mild ectasia of sinusoids with an increase in the number of circulating erythrocytes (congestion), and in one case, in the periportal space, extramedullary haematopoeisis was also noticed. No additional lesions were observed in other organs. On immunohistochemistry, immunolabelling for Mycoplasma was visualized as a finely granular intracytoplasmic reaction on the respiratory epithelium (Figure 1(d)).

2.3. Molecular Detection and Genome Sequencing. Tracheal and cloacal swabs were obtained using sterile cotton swabs, rotated against the mucosa of trachea or cloaca and kept in tubes containing 0.5 mL of PBS, pH 7.2. Two hundred μL of transport buffer (PBS) of the swabs or 20 mg of lung and trachea was used for DNA extraction using the commercial kits QIAamp DNA Mini kit (QIAGEN) and GenElute Mammalian Genomic DNA Miniprep kit, (Merck, Italy) for swabs and tissues, respectively, according to the manufacturer’s instructions.

A conventional PCR, targeting a fragment of 1013 bp of the 16S rRNA gene, was used to detect Mycoplasma spp. (Lierz et al. 2007). A nested PCR protocol targeting the 16S rRNA gene was used to detect Chlamydia spp. (Messmer et al. 1997). This method discriminates Chlamydia pneumoniae from Chlamydia psittaci amplifying fragments of 221 or 127 bp, respectively. PCR products of the expected size were purified using a commercial kit (Qiagroup, Qiagen, Germany) and directly submitted for sequencing on both strands with the same forward and reverse primers (Biofab srl, Italy). By PCR, Mycoplasma spp. DNA was amplified from the tracheal swabs and tracheal tissue of the tested animals, while no DNA amplification was detected in cloacal swabs and lung tissues. Amplicon sequences were assembled using BioEdit (version 7.2) [8]. Assembled sequences were aligned with nucleotide database available from GenBank using the basic local alignment search tool (BLAST) (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to find similarities with Mycoplasma sequences. Amplicons were sequenced and BLAST analysis resulted more than 99% identity with the homologous 16S rRNA gene sequences of Mycoplasma columbinasale. The sequences were submitted to GenBank and assigned the accession numbers MW732628 and MW732629. All the specimens (tracheal swab, cloacal swab, lung and trachea) tested negative for Chlamydia sp. by nested PCR.

2.4. Microbiological Examination. Microbiological assessment was performed on lung tissues and tracheal swabs collected during post-mortem examination. Multiple lung specimens were individually homogenized in sterile PBS. One-hundred microliters of these and tracheal swabs were spread on 5% defibrinated sheep blood agar, MacConkey agar and Mannitol salt agar (Liofilchem, Italy). The plates were incubated at 37°C in aerobic conditions and 5-10% CO₂ for 24-48 h. The identification of bacteria was performed by examining colony characteristics, Gram staining, and use of biochemical tests and commercially available Analytical Profile Index (API) kits (bioMerieux, Étoile, France). The samples were cultured also on Sabouraud dextrose agar (Liofilchem, Italy) supplemented with and without chloramphenicol at 28 and 35°C for up to 7 days for fungal examination. Tracheal swabs from both pigeons grew sporadic mixed cultures containing from two to three different bacterial species. Bacteria were isolated as scanty colonies and belonged to genus Cronobacter, Corynebacterium, Enterococcus and Bacillus with no predominating organism. Fungi were not detected from tracheal swabs. Lung specimens were negative for bacteria and fungi.

2.5. Treatment and Clinical Follow-Up. Tylosin was administered subcutaneously to birds with respiratory signs (BID for 5 days; 25 mg/kg). For clinically healthy birds in close aviaries, administration was set as 5 gr of water soluble tylosin/L drinking water for 7 days, as reported in the leaflet. Birds were clinically monitored for the entire length of the treatment and routine monitoring of the healthy status of the breeding aviary is performed yearly. The treatment with tylosin successfully led to the complete resolution of the clinical condition. Lack of recurrence of clinical signs was reported in the breeding aviary in the following years.

3. Discussion and Conclusion

In this study, molecular detection and immunohistochemistry were used to detect and identify Mycoplasma spp. in tissues of domestic pigeons (Columba livia var. domestica) submitted for postmortem investigations during an episode of respiratory disease and low birds’ mortality in a pigeon breeding farm in central Italy. Complete necropsy and gross and histopathological investigation were performed in association with the previously mentioned ancillary diagnostic tests.

Some Mycoplasma spp. organisms are known pathogens in birds, causing every year severe economic loss in the poultry industry [9]. In pigeons, the role of these biological
agents is not completely understood. Few reports of mycoplasma-associated disease are available in literature, often lacking a clear agent-lesions association. Additionally, the isolation of the same agents in healthy birds is a confounding factor for cause-and-effect relationship [3, 4, 6, 7].

In this study, a diffuse tracheal hyperaemia with moderate mucosal thickening was noticed as a major finding in association with nonspecific splenic-hepatomegaly and diffuse multiorgan congestion. On histological examination, the most striking lesions were the epithelial hyperplasia associated with a moderate to severe lymphohistiocytic tracheitis. Epithelial hyperplasia is commonly reported in mycoplasma-associated disease in domestic and wild avian species [10, 11]. Particularly in birds, the same pattern of lesions has been described in M. gallisepticum, naturally infected house finches (Carpodacus mexicanus), and experimentally infected domestic canaries (Serinus canaria domestica) [11, 12], and the increased tracheal mucosal thickness is usually adopted for M. gallisepticum disease severity measurement [13, 14]. Regarding as the core of disease pathogenesis, M. gallisepticum attachment to the host cell elicits a sturdy lymphoproliferative host immune response which is responsible for tissue damage (immunopathology) at the colonization site [15, 16].

On immunohistochemistry, specific Mycoplasma labeling was seen on the apical surface of the tracheal respiratory epithelium as reported in previous papers, confirming the presence of the microorganism in close association with the lesions [17]. Therefore, immunohistochemistry performed with pan-avian mycoplasma monoclonal antibody proved itself useful for localizing the Mycoplasma within the tissue section, hence helping the achievement of the diagnosis.

Regarding the molecular detection and genomic sequencing, although the identification of M. columbinasale has been reported in healthy pigeons raising awareness on its possible role as commensal and part of the normal respiratory microbiome of pigeons [5], the association with the previously mentioned data supports its role as agent of disease [7].

The role of M. columbinasale in the development of the previously described lesions and clinical signs was also suspected and based on the results of microbiology testing. A mixed culture with scarce no predominating organisms that are not usually pathogens of avian upper respiratory tract [18] is less likely to produce the observed disease.

A possible limitation of this study is the lack of Mycoplasma spp. cultivation which is performed in specialised laboratories, and it is known for the tediousness and the difficulties that come with it. Also, the sensitivity of Mycoplasma cultivation may be variable due to low bacterial load and copresence of different Mycoplasma species with different growing requirements [19, 20].

In addition, this study lacks of data regarding possible concurrent infections (e.g., Pigeon circovirus (PiCV)) that could have contributed to the development of an immune suppressive state with consequent establishment of M. columbinasale as an opportunistic pathogen [5, 21, 22]. Although histological lesions found in this case are similar to what can be observed during M. gallisepticum infection, those alone do not allow proposing analogies with the pathogenesis of this major avian mycoplasmal pathogen. Additionally, it is not known if M. columbinasale is able to exert an immunosuppressive effect in the same way as M. gallisepticum does [23–25]. Taken into account that clinical signs were observed in adult birds only, it is possible that the physical activity performed by this category of pigeons may have predisposed them to disease development. Further studies are needed to better understand any interrelation between M. columbinasale and the pigeon immune system.

Finally, the complete resolution of the clinical condition in absence of recurrence of clinical signs was obtained the administration of tylosin. The successful outcome of the treatment further supported, as “ex-juvantibus diagnosis”, the possible involvement of M. columbinasale in the respiratory disease.

In conclusion, the association of clinical signs, gross and histologic lesions, molecular detection of M. columbinasale and its immunohistochemical identification in lesions, and the clinical resolution with administration of tylosin suggest for this agent its possible association to respiratory disease, poor performance and low mortality in domestic pigeons.

**Data Availability**

Sequences are available on GenBank with assigned accession numbers MW732628 and MW732629.

**Disclosure**

Giuseppe Giglia current affiliation is Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL, Utrecht, Netherlands.

**Conflicts of Interest**

Authors declare no conflicts of interest.

**Acknowledgments**

This research was partially funded by the Italian Ministry of Health, RC IZS VE 14/12. The authors thank Luca Stefanelli and Sara Leto for the technical support in the histology lab.

**References**

[1] A. V. Gautier-Bouchardon, “Antimicrobial resistance in mycoplasmapp,” in Antimicrobial Resistance in Bacteria from Livestock and Companion Animals, pp. 425–446. ASM Press, Washington, DC, USA, 2018.

[2] N. Okwara, “Avian Mycoplasmosis a review,” Journal of Agriculture and Veterinary Science, vol. 9, pp. 6–10, 2016.

[3] T. Hellebuyck, A. Garmyn, L. De Cooman, F. Boyen, F. Pasmans, and A. Martel, “Mycoplasma columbinum isolated from a racing pigeon (Columba livia) with arthritis,” Journal of Avian Medicine and Surgery, vol. 28, no. 3, pp. 240–241, 2014.

[4] F. Jordan, J. Howse, M. Adams, and O. Fatunmbi, "The isolation of mycoplasma columbinum and M columborale from...
feral pigeons,” *The Veterinary Record*, vol. 109, no. 20, pp. 450–450, 1981.

[5] I. F. Keymer, R. H. Leach, R. A. Clarke, M. E. Bardsley, and R. R. McIntyre, “Isolation of mycoplasmas from racing pigeons (Columbia livia),” *Avian Pathology*, vol. 13, no. 1, pp. 65–74, 1984.

[6] T. Shimizu, H. Erno, and H. Nagatomo, “Isolation and Characterization of Mycoplasma columbinum and Mycoplasma columbora,” *Two New Species from Pigeons,* International Journal of Systematic Bacteriology, vol. 28, no. 4, pp. 538–546, 1978.

[7] I. Türcsányi, A. Bistyák, K. Matiz, S. Kecskeméti, G. Bölcske, and I. Kiss, “Isolation of mycoplasma columbinasale from pigeons in Hungary,” *The Veterinary Record*, vol. 157, no. 8, pp. 235–236, 2005.

[8] T. A. Hall, “BiolEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT,” in *Nucleic acids symposium series*, pp. 95–98, London, UK, (January, 1999).

[9] N. Ferguson-Noel, N. K. Armour, A. H. Noormohammadi, M. El-Gazzar, and J. M. Bradbury, “Mycoplasmosis,” in *Diseases of Poultry*, pp. 907–965, Wiley, 2019.

[10] M. Gouffaux, H. Vindevogel, G. Meulemans, A. Dewaele, and P. Halen, “Elements du diagnostic histopathologique différentiel des principales affections respiratoires de la poule,” *Avian Pathology*, vol. 6, no. 1, pp. 61–76, 1977.

[11] M. P. Luttrell, D. E. Stalkehnacht, J. R. Fischer, C. T. Sewell, and S. H. Kleven, “Natural mycoplasma gallisepticum infection in a captive flock of house finches,” *Journal of Wildlife Diseases*, vol. 34, no. 2, pp. 289–296, 1998.

[12] D. M. Hawley, J. Grodio, S. Frasca, L. Kirkpatrick, and D. H. Ley, “Experimental infection of domestic canaries (Serinus canaria domestica) with mycoplasma gallisepticum: a new model system for a wildlife disease,” *Avian Pathology*, vol. 40, no. 3, pp. 321–327, 2011.

[13] T. Nunoya, M. Tajima, T. Yagihashi, and S. Sannai, “Evaluation of respiratory lesions in chickens induced by mycoplasma gallisepticum,” *The Japanese Journal of Veterinary Science*, vol. 49, no. 4, pp. 621–629, 1987.

[14] K. G. Whitbread, K. E. Harrigan, and S. H. Kleven, “Standardized method of aerosol challenge for testing the efficacy of mycoplasma gallisepticum vaccines,” *Avian Diseases*, vol. 40, no. 3, pp. 654–660, 1996.

[15] G. F. Browning, A. H. Noormohammadi, and P. F. Markham, “Identification and characterization of virulence genes in mycoplasmas,” in *Mollicutes-Molecular Biology and Pathogenesis*, G. F. Browning and C. Citti, Eds., pp. 77–90, Caister Academic Press, Norfolk, UK, 2014.

[16] S. M. Szczepanek and L. K. Silbarg, “Host immune responses to mycoplasmas,” in *Mollicutes-Molecular Biology and Pathogenesis*, G. F. Browning and C. Citti, Eds., pp. 273–288, Caister Academic Press, Norfolk, UK, 2014.

[17] S. Gharabeh and A. Hailat, “Mycoplasma gallisepticum experimental infection and tissue distribution in chickens, sparrows, and pigeons,” *Avian Pathology*, vol. 40, no. 4, pp. 349–354, 2011.

[18] A. M. Fudge, “Diagnosis and treatment of avian bacterial disease,” *Seminars in Avian and Exotic Pet Medicine*, vol. 10, no. 1, pp. 3–11, 2001.

[19] B. S. Cook, J. G. Beddow, L. Manso-Silván, G. A. Maglennon, and A. N. Rycroft, “Selectice medium for culture of mycoplasma hyopneumoniae,” *Veterinary Microbiology*, vol. 195, pp. 158–164, 2016.

[20] B. Kashyap, S. Kumar, G. R. Sethi, B. C. Das, and S. R. Saigal, “Comparison of PCR, culture & serological tests for the diagnosis of mycoplasma pneumoniae in community-acquired lower respiratory tract infections in children,” *The Indian Journal of Medical Research*, vol. 128, no. 2, pp. 134–139, 2008.

[21] T. Stenzel, D. Dziewulska, B. Tykałowski, and A. Koncicki, “The clinical infection with pigeon circovirus (Picv) leads to lymphocyte b apoptosis but has no effect on lymphocyte t subpopulation,” *Pathogens*, vol. 9, no. 8, pp. 1–12, 2020.

[22] D. Todd, “Circoviruses: immunosuppressive threats to avian species: a review,” *Avian Pathology*, vol. 29, no. 5, pp. 373–394, 2000.

[23] K. Ganapathy and J. M. Bradbury, “Effects of cyclosporin a on the immune responses and pathogenesis of a virulent strain of mycoplasma gallisepticum in chickens,” *Avian Pathology*, vol. 32, no. 5, pp. 495–502, 2003.

[24] J. Mohammed, S. Frasca, K. Cecchini et al., “Chemokine and cytokine gene expression profiles in chickens inoculated with mycoplasma gallisepticum strains Rlow or GT5,” *Vaccine*, vol. 25, no. 51, pp. 8611–8621, 2007.

[25] F. Rharbaoui, B. Drabner, S. Borsutzky et al., “The mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant,” *European Journal of Immunology*, vol. 32, no. 10, pp. 2857–2865, 2002.